These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 16135249)

  • 21. Mechanisms of melanocyte death in vitiligo.
    Chen J; Li S; Li C
    Med Res Rev; 2021 Mar; 41(2):1138-1166. PubMed ID: 33200838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo.
    Palermo B; Campanelli R; Garbelli S; Mantovani S; Lantelme E; Brazzelli V; Ardigó M; Borroni G; Martinetti M; Badulli C; Necker A; Giachino C
    J Invest Dermatol; 2001 Aug; 117(2):326-32. PubMed ID: 11511311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells.
    Cui J; Bystryn JC
    Arch Dermatol; 1995 Mar; 131(3):314-8. PubMed ID: 7887661
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IgG anti-melanocyte antibodies purified from patients with active vitiligo induce HLA-DR and intercellular adhesion molecule-1 expression and an increase in interleukin-8 release by melanocytes.
    Li YL; Yu CL; Yu HS
    J Invest Dermatol; 2000 Dec; 115(6):969-73. PubMed ID: 11121127
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients.
    van den Boorn JG; Konijnenberg D; Dellemijn TA; van der Veen JP; Bos JD; Melief CJ; Vyth-Dreese FA; Luiten RM
    J Invest Dermatol; 2009 Sep; 129(9):2220-32. PubMed ID: 19242513
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients.
    Luiten RM; Kueter EW; Mooi W; Gallee MP; Rankin EM; Gerritsen WR; Clift SM; Nooijen WJ; Weder P; van de Kasteele WF; Sein J; van den Berk PC; Nieweg OE; Berns AM; Spits H; de Gast GC
    J Clin Oncol; 2005 Dec; 23(35):8978-91. PubMed ID: 16260696
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo.
    Uchi H; Stan R; Turk MJ; Engelhorn ME; Rizzuto GA; Goldberg SM; Wolchok JD; Houghton AN
    Adv Immunol; 2006; 90():215-41. PubMed ID: 16730265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Melanocyte-specific immune response in a patient with multiple regressing nevi and a history of melanoma.
    Speeckaert R; van Geel N; Luiten RM; van Gele M; Speeckaert M; Lambert J; Vermaelen K; Tjin EP; Brochez L
    Anticancer Res; 2011 Nov; 31(11):3697-703. PubMed ID: 22110189
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IFN-γ-induced PD-L1 expression on human melanocytes is impaired in vitiligo.
    Willemsen M; Krebbers G; Tjin EPM; Willemsen KJ; Louis A; Konijn VAL; Narayan VS; Post NF; Bakker WJ; Melief CJM; Bekkenk MW; Luiten RM
    Exp Dermatol; 2022 Apr; 31(4):556-566. PubMed ID: 34758170
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor antigens isolated from a patient with vitiligo and T-cell-infiltrated melanoma.
    Kiniwa Y; Fujita T; Akada M; Ito K; Shofuda T; Suzuki Y; Yamamoto A; Saida T; Kawakami Y
    Cancer Res; 2001 Nov; 61(21):7900-7. PubMed ID: 11691810
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD8+ T cells from vitiligo perilesional margins induce autologous melanocyte apoptosis.
    Wu J; Zhou M; Wan Y; Xu A
    Mol Med Rep; 2013 Jan; 7(1):237-41. PubMed ID: 23042234
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autoimmune etiology of generalized vitiligo.
    Le Poole IC; Luiten RM
    Curr Dir Autoimmun; 2008; 10():227-43. PubMed ID: 18460889
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Melanocyte-specific immune response in melanoma and vitiligo: two faces of the same coin?
    Wankowicz-Kalinska A; Le Poole C; van den Wijngaard R; Storkus WJ; Das PK
    Pigment Cell Res; 2003 Jun; 16(3):254-60. PubMed ID: 12753398
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autoimmune aspects of depigmentation in vitiligo.
    Le Poole IC; Wañkowicz-Kaliñska A; van den Wijngaard RM; Nickoloff BJ; Das PK
    J Investig Dermatol Symp Proc; 2004 Jan; 9(1):68-72. PubMed ID: 14870989
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The antibody response against MART-1 differs in patients with melanoma-associated leucoderma and vitiligo.
    Teulings HE; Willemsen KJ; Glykofridis I; Krebbers G; Komen L; Kroon MW; Kemp EH; Wolkerstorfer A; van der Veen JP; Luiten RM; Tjin EP
    Pigment Cell Melanoma Res; 2014 Nov; 27(6):1086-96. PubMed ID: 25043574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A mouse model of vitiligo based on endogenous auto-reactive CD8 + T cell targeting skin melanocyte.
    Chen D; Xu Z; Cui J; Chen T
    Cell Regen; 2022 Oct; 11(1):31. PubMed ID: 36182982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lymphocytes cytotoxic to uveal and skin melanoma cells from peripheral blood of ocular melanoma patients.
    Kan-Mitchell J; Liggett PE; Harel W; Steinman L; Nitta T; Oksenberg JR; Posner MR; Mitchell MS
    Cancer Immunol Immunother; 1991; 33(5):333-40. PubMed ID: 1831067
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma.
    Robbins PF; El-Gamil M; Li YF; Zeng G; Dudley M; Rosenberg SA
    J Immunol; 2002 Nov; 169(10):6036-47. PubMed ID: 12421991
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides.
    Jäger E; Maeurer M; Höhn H; Karbach J; Jäger D; Zidianakis Z; Bakhshandeh-Bath A; Orth J; Neukirch C; Necker A; Reichert TE; Knuth A
    Int J Cancer; 2000 May; 86(4):538-47. PubMed ID: 10797269
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma.
    Anichini A; Mortarini R; Maccalli C; Squarcina P; Fleischhauer K; Mascheroni L; Parmiani G
    J Immunol; 1996 Jan; 156(1):208-17. PubMed ID: 8598464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.